Diagnosing and managing Barrett's esophagus.
Although significant advances have been made in our understanding of Barrett's esophagus (BE), several questions remain. The answers will affect the way BE is defined, identified, monitored, and treated. This paper reviews the current definition of BE, the rationale for surveillance and risk stratification, the possible role of p53 mutations in adenocarcinoma, and the relationships among metaplasia, dysplasia, and adenocarcinoma.
Sampliner
R E
RE
D000230:Adenocarcinoma / Q000209:etiology / Q000473:pathology; D001471:Barrett Esophagus / Q000150:complications* / Q000175:diagnosis*; D001706:Biopsy; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000209:etiology / Q000473:pathology*; D004947:Esophagus / Q000473:pathology; D005764:Gastroesophageal Reflux / Q000150:complications; D006801:Humans; D007414:Intestinal Neoplasms / Q000209:etiology / Q000473:pathology*; D007422:Intestines / Q000473:pathology; D012307:Risk Factors